Hepatitis C Awareness and Risky Injection Behaviors among Injection Drug Users in Treatment PT Korthuis 1, D Feaster 2, Z Gomez 2, M Das-Douglas 3, S Tross.

Slides:



Advertisements
Similar presentations
Risk Factors for Early Syphilis Among Men Who Have Sex With Men Seen in an STD Clinic – San Francisco, STD Prevention Conference: March 10, 2004.
Advertisements

Predictors of Change in HIV Risk Factors for Adolescents Admitted to Substance Abuse Treatment Passetti, L. L., Garner, B. R., Funk, R., Godley, S. H.,
The effect of gender specific HIV prevention interventions on heterosexual anal sex among men and women in substance abuse treatment Donald A. Calsyn,
Differences in Characteristics of Heroin Inhalers and Injectors at Admission to Treatment J. C. Maxwell, R. T. Spence, & T. M. Bohman UT Center for Social.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
Risky Behavior: Perceived Risk of Infectious Disease in Youth Entering Alcohol/Drug Treatment Risky Behavior: Perceived Risk of Infectious Disease in Youth.
Correlates of polydrug use among injection drug users: The role of socioeconomic stress and quality of life Marrero CA, Robles RR, Reyes JC, Matos TD,
Behavioral Intention and Partner Type on Condom Use Among Men in Drug Treatment Yong S. Song, PhD, University of California, San Francisco Donald Calsyn,
HIV Risk Behaviors and Alcohol Intoxication among Injection Drug Users in Puerto Rico Tomás D. Matos, MS Center for Addiction Studies Universidad Central.
C. Andres Bedoya, PhD Behavioral Medicine Service Department of Psychiatry Massachusetts General Hospital / Harvard Medical School Factors related to high-risk.
High Risk Sharing Behaviors: The Effect of Sex within Injecting Partnerships Meghan D. Morris, PhD, MPH Postdoctoral Research Fellow Department of Epidemiology.
Killing the Pain: Prescription Drug Abuse and Other Risky Behaviors in Rural Appalachia Jennifer R. Havens, PhD, MPH Department of Behavioral Science Center.
Substance Use, Substance Choice, and Unprotected Sex among Young Asian/Pacific Islander (API) Men Who Have Sex with Men (MSM) Kyung-Hee Choi, 1 Don Operario,
Drug Trends in Washington State & King County Caleb J. Banta-Green MPH MSW Alcohol & Drug Abuse Institute University of Washington
HIV Risk Factors and HIV Prevalence Among Street Youth in Russia, Yulia Batluk, HealthRight International.
Rectal Lubricant Use & Incident STIs at 9 US STD Clinics 1 UCLA Fielding School of Public Health, 2 UCLA David Geffen School of Medicine, 3 Dept. of Epidemiology.
Afghanistan’s Present IDUs-HIV/AIDS Situation and future action plan Dr.Saifur-Rehman NACP Director April,11,2007 Islamic Republic of Afghanistan Ministry.
HIV Infection Among Those with an Injection Drug Use*- Associated Risk, Florida, 2012 Florida Department of Health HIV/AIDS and Hepatitis Section Division.
Efficacy of a Peer-Led Network Intervention in Reducing HIV Incidence among People Who Inject Drugs in Ukraine: Preliminary Results from a Clustered Randomized.
Population-based estimates of prevalence of HIV, HBV and HCV and HIV-related risk behaviors among male injecting drug users in Lagos, Nigeria Waimar Tun.
HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,
We conducted a cross-sectional study using interviewer- administered surveys and qualitative interviews of young (aged 18-30) of final sample 164 PWID.
Louise Haynes MSW Medical University of South Carolina Lead Investigators: Lisa Metsch PhD Miller School of Medicine, University of Miami Grant Colfax.
FUTURE HIV RESEARCH EFFORTS PLANNED FOR THE CLINICAL TRIALS NETWORK James L. Sorensen, Ph.D. Susan Tross, Ph.D. Raul Mandler, M.D. University of California,
Preventing Medical Complications of Injection Drug Use Keith Heinzerling, MD, MPH UCLA Seminars in Addiction Psychiatry Course August 11, 2005.
Effects of an HIV/AIDS peer prevention intervention on sexual and injecting risk behaviors among injecting drug users (IDUs) and their risk partners in.
HIV Risk-Reduction: Counselor Training for a Randomized Clinical Trial Louise Haynes 1, Tim Matheson 2, Kathleen Brady 1, Lisa Metsch 3 1 Psychiatry and.
Tripling of methamphetamine use among homeless and marginally housed persons, Judith Hahn, Moupali Das-Douglas, Grant Colfax, Andrew Moss, David.
Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.
CARIBBEAN BASIN AND HISPANIC ADDICTION TECHNOLOGY TRANSFER CENTER Effects of a Two-facet Intervention to Reduce HIV Risk Behaviors Among Hispanic Drug.
Increased exposure to an HIV risk reduction protocol associated with a reduction in drug abuse severity Louise F. Haynes 1 ; Rickey E. Carter 1 ; Amy E.
HIV Infection Among Those with an Injection Drug Use*-Associated Risk, Florida, 2014 Florida Department of Health HIV/AIDS Section Division of Disease.
HIV TESTING IN DRUG ABUSE TREATMENT James L. Sorensen, Ph.D. University of California, San Francisco and San Francisco General Hospital Presentation at.
Unhealthy alcohol use in other drug users identified by screening in primary care Secondary analysis of ASPIRE trial data Funded by NIDA 1 R01 DA
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Adoption of HIV Counseling and Testing Following Completion of Randomized Clinical Trial Louise Haynes 1, Beverly Holmes 2 Camille Peay 2, Lisa Metsch.
Reducing Sex under the Influence for Substance Abuse Treatment Patients Symposium Presentation at the American Psychological Association Annual Convention,
Methods Data for this NIDA-funded HIV prevention trial (Project WORTH) were drawn from 337 women offenders under community supervision, who reported using.
Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS
SCHOOL OF NURSING UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Not Ready for Prime Time? A Web-Based SBIRT Intervention in an Urban Safety-Net HIV Clinic Carol.
CEACEA CENTROCENTRO DE ESTUDIOS EN ADICCION Testing an Intervention Model to Reduce HIV/AIDS Among Hispanic Drug Users Residing in Puerto Rico Robles RR,
HIV Infection among Those with an Injection Drug Use*-Associated Risk, Florida, 2011 HIV/AIDS & Hepatitis Program *Injection Drug Use (IDU) data in this.
Adoption of HIV Counseling and Testing Following Completion of Randomized Clinical Trial Louise Haynes 1, Beverly Holmes 2, Anna Amberg 2, Kathleen Brady.
Social Context and the Health of Sex Workers in San Francisco Deborah Cohan, MD, MPH 1, Johanna Breyer, MSW 2, Cynthia Cobaugh 2, Charles Cloniger, NP,
Effects of Pharmacy Syringe Access Among Young Heroin Injectors Results IDU needle sharing decreased after the enactment of the pharmacy access law in.
Jennifer R. Havens, PhD, MPH Associate Professor
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction Jennifer Schroeder, David Epstein, Katherine Belendiuk, Jessica Willner-Reid, John.
Howard Newville 1, James L. Sorensen 1, Donald A. Calsyn 2 1 University of California, San Francisco, San Francisco, CA 2 University of Washington, Seattle,
Stephen Nkansah-Amankra, PhD, MPH, MA 1, Abdoulaye Diedhiou, MD, PHD, H.L.K. Agbanu, MPhil, Curtis Harrod, MPH, Ashish Dhawan, MD, MSPH 1 University of.
Housing Status and HIV Risk Behaviors Among Homeless and Housed Persons with HIV in the United States The findings and conclusions in this presentation.
Trends in the Prevalence of Hepatitis C and Hepatitis B and HIV in Seattle Injection Drug Users, 18 – 30 years old, Richard Burt, Holly Hagan,
Estimating the population impact of homelessness on HIV viral suppression among people who use drugs Brandon DL Marshall, 1 Beth Elson, 1 Sabina Dobrer,
Background  Substance abusers are at risk for HIV and other STIs.  Anal intercourse (AI) is riskier than vaginal intercourse.  Studies of AI have focused.
Association of Syringe Source and Syringe Sharing in New York City Results from National HIV Behavioral Surveillance among Injection Drug Users Samuel.
Clare Meernik, MPH 1 ; Anna McCullough, MSW, MSPH, CTTS 1 ; Leah Ranney, PhD 1 ; Barbara Walsh 2 ; Adam O. Goldstein, MD, MPH 1 Predictors of Quit for.
Behavioral Health and HIV/HCV Risk Behavior Among Young African American IDUs Patricia M Morse, LCSW, PhD, Edward V, Morse, PhD, Samuel Burgess, MA, MPH.
Readiness To Change HIV/HCV Risk Behavior Among Young African American IDUs. Edward V Morse, PhD, Tulane University Health Sciences Center, Department.
138 th American Public Health Association Annual Meeting Denver, Colorado November 8, 2010 Determinants of HIV Testing Among High School Students with.
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
Trends in Access to Substance Abuse Treatment for Women and Men: Jeanne C. Marsh, PhD, Hee-Choon Shin, PhD, Dingcai Cao, PhD University of Chicago.
Health Risks Resulting from Injection Drug Use. Drugs most commonly used through injection are: Cocaine Heroine Methamphetamines Steroids.
PURPOSE BACKGROUND RESULTS STUDY DESIGN & METHODS HIV Risk Behaviors Among Male Prisoners Participating in a Randomized Clinical Trial of Methadone Maintenance.
Daniulaityte, R., Falck, R., & Carlson, R. Introduction
Hatch-Maillette, M. 1, Calsyn, D. A1,2, Doyle, S. 1, Woods, A
Kristen Williams, Jonathan J.K. Stoltman, and Mark K. Greenwald
Understanding Associations Between Serious Mental Illness and Hepatitis C among Veterans: A National Multivariate Analysis Seth Himelhoch, MD, MPH,1,2.
Lung Cancer Screening: Do Individual Health Beliefs Matter?
Rowe, KA1, Tesoriero, JM1, Davis, SJ1, Heavner, KK1, Rothman, J2,
VACS Scientific Meeting Houston, TX February 2004
Presentation transcript:

Hepatitis C Awareness and Risky Injection Behaviors among Injection Drug Users in Treatment PT Korthuis 1, D Feaster 2, Z Gomez 2, M Das-Douglas 3, S Tross 4, K Wiest 5, A Douaihy 6, RN Mandler 7, JL Sorensen 3, G Colfax 8, PE Penn 9, D Lape 5, L Metsch 2. 1 Oregon Health and Science University; 2 University of Miami Miller School of Medicine; 3 University of California, San Francisco; 4 Columbia University; 5 CODA; 6 University of Pittsburgh School of Medicine; 7 National Institute on Drug Abuse; 8 San Francisco Department of Public Health; 9 La Frontera;

Acknowledgements No Conflicts of Interest Funding by NIDA Clinical Trials Network PI Lisa Metsch Co-authors Participants

Background Injection drug use (IDU) remains a leading cause of HIV and Hepatitis C (HCV) transmission worldwide Among IDU, predictors for HCV seroconversion include sharing needles, syringes, & cotton. Across multiple U.S. studies, 35-65% of current IDU report needle sharing, but access to clean needles has improved.

Awareness of Infectious Status and Risk Behaviors HIV: Those aware of HIV infection decrease risky sexual behavior 68% 1 but not IDU risk 2 HCV: – Survey of 197 IDU’s in Denver : HCV-aware engaged in fewer HCV risk behaviors 3 – Survey of 213 Swedish IDU: knowledge of HCV not associated with change in risky behaviors 4 – Survey of 337 IDU in Seattle: HCV-aware more likely to “sero-sort” needle sharing 5 1 Marks G, JAIDS 2005;39:446 2 Avants SK, JSAT 200;19:15 3 Kwiatkowski CF Addiction 2002;97: Norden, Scan J Infect Dis 2009;41: Burt RD, Drug & Alc Dep 2009;105: 215

Research Question & Hypothesis What are current injection behaviors among IDU’s in treatment? – Hypothesis: Needle sharing lower than historically high rates. Is Awareness of Self-reported HCV status associated with less risky injection behaviors? – Hypothesis: IDU aware of HCV status will report less sharing of needles/works

Study Setting and Participants NIDA CTN0032: A randomized trial of 3 HIV testing & counseling strategies for persons presenting for addiction treatment Sites: 12 community-based U.S. addiction treatment programs Eligibility: Age >18, English-speaking, HIV- negative Analytic Sample: Those reporting recent IDU (= use in last 6 mo)

Measures Independent Variable: Self-reported awareness of HCV status (“Are you positive for Hepatitis C?”)—Yes, No Dependent Variable: Self-reported sharing of needles or works in past 6 months Covariates: age, gender, race, education, source of needles, & specific substances used

Analysis Descriptive statistics for frequency of drug use, injection behaviors, and needle sharing Multivariate logistic regression to estimate associations between HCV status and sharing needles/works – Covariates included in Multivariate analysis if p<.20 in bivariate analysis or a priori significance

Results: Injection Drug Use in Past 6 Months 245/1281 (19%) of CTN0032 participants reported recent IDU

Participant Characteristics, by HCV Self Report (n=245) HCV Positive (n = 92) HCV Negative (n = 153) Total (n = 245) p-value Mean Age (SD)45.3(8.80)35.6(10.6)39.3(11.0)<.001 Male Gender (%)4447.8% % Race/Ethnicity (%).251 White5559.8% % % Hispanic1711.1%1819.6%3514.3% Black99.8%1711.1%2610.6% Other1010.9%138.5%239.4% Employed (%)2123.1%3019.6%5120.9%.519 Education (%).927 < High School2830.4%4328.1%7129.0% High School3234.8%5535.9%8735.5% ≥ Some College3234.8%5535.9%8735.5% Court Mandated Treatment (%) %3220.9%4920.0%.644 Jailed last 6 mo (%)2021.7%5535.9%7530.6%.019

Non-Injection Use in Past 6 Months, by HCV Self Report (n=245) HCV PositiveHCV NegativeTotalp-value Ecstasy 44.3%2214.4%2610.6%.014 Opioid % % %.963 Powder Cocaine %5535.9%7430.2%.012 Crack %6743.8% %.653 Pot %8152.9% %.078 Tranquilizer %5737.3%8735.5%.462 Painkillers %7549.0% %.019 Speed %3724.2%5422.0%.297 Hallucinogens 22.2%1811.8%208.2%.008 Alcohol to Intoxication % % %.001

Injection Drug Use in Past 6 Months, by HCV Self Report (n=245) HCV PositiveHCV NegativeTotalp-value Powder Cocaine2223.9%4328.1%6526.5%.472 Crack99.8%117.2%208.2%.473 Heroin & Powder Cocaine1010.9%1811.8%2811.4%.831 Heroin & Crack55.4%32.0%83.3%.138 Cocaine4831.4%2729.3%7530.6%.739 Heroin & Speed88.7%117.2%197.8%.670 Speed1213.0%1912.4%3112.7%.887 Dilaudid66.5%138.5%197.8%.576 Heroin6368.5%8454.9% %.036 Painkillers66.5%2315.0%2911.8%.046 Methadone22.2%95.9%114.5%.175 Opioids6975.0% % %.337 Barbiturates11.1%21.3%31.2%.879 Tranquilizers & Barbiturates 11.1%32.0%41.6%.601 Injected Multiple Drugs at a Time % % %.133

Injection Frequency and Needle Source in Past 6 Months, by HCV Self Report Positive (n = 91)Negative (n = 152)Total (n = 244)p-value Frequency of injection.206 Less than once a month %3523.2%5522.6% 1-3 times a month %2113.9%3715.2% About once a week %74.6%187.4% > Once a week, but not every day %4429.1%6928.4% Every day %4429.1%6426.3% Where Needles Obtained Diabetic %3422.4%5120.8%.485 Street %2516.3%3815.5%.644 MS/Hepatitis 33.3%21.3%52.0%.295 Drug store %8454.9% %.161 Shooting gallery 55.4%53.3%104.1%.407 Needle exchange program %2818.3%6124.9%.002 Other %2315.0%3915.9%.625

Needle Cleaning in Past 6 Months, By HCV Self Report PositiveNegativeTotalp-value Needle Cleaning Habits (n=244).310 Always use new needles %7751.3% % Always clean before shooting up %1912.7%3514.5% Always clean after shooting up %3724.7%5924.5% Sometimes clean needle %149.3%2811.6% Never clean needle 33.3%32.0%62.5% Needle Cleaning Method (n=125) Clean with bleach %3446.6%7156.3%.009 Clean with soap and water %3142.5%4938.9%.334 Clean with alcohol 47.5%1824.7%2217.5%.013 Clean with boiling water 611.3%1317.8%1915.1%.315 Did not clean needles 0.0%11.4%1.8%.392

Needle Sharing in Last 6 Months 94/244 (38.5%) current IDU reported Needle Sharing in Past 6 Months – 88% Both Receptive and Distributive sharing – 8% Distributive Sharing only – 3% Receptive Sharing only

Needle Sharing in Last 6 Months 94/244 (38.5%) current IDU reported Needle Sharing in Past 6 Months – 88% Both Receptive and Distributive sharing – 8% Distributive Sharing only – 3% Receptive Sharing only `Positive (n = 91)Negative (n = 152)Total (n = 244)p-value Sharing Needles/Works4144.6%5334.9%9438.5%

Multivariate Associations with Needle Sharing Participant Characteristics % Needle Sharing (n = 244) OR 95% Confidence Interval Agen/a 0.95 (0.92, 0.99) Male31.8% 0.52 (0.28, 0.96) Race/Ethnicity White 42.9% Ref Hispanic 36.0%2.11 (0.82, 5.43) Black 36.6%2.04 (0.65, 6.41) Other 47.8%2.06 (0.75, 5.66) Education (%) < High School 51.4% Ref High School 34.5%0.50 (0.24, 1.05) ≥ Some College 32.2%0.47 (0.22, 0.99) Hepatitis C Positive 44.6%2.37 (1.15, 4.88) Used Street Needles 57.9%2.66 (1.18, 5.97) Any Opioid 46.3% 4.43(1.44, 13.7) Any Pot 47.9% 2.10(1.09, 4.03) IDU Crack 65.0% 3.19(1.07, 9.49)

Limitations Self-reported HCV status – But predictive value of self-reported positive 94% 1 – Belief about status more important behavioral determinant than biologic HCV status Cross-sectional Design limits causal inference – Greater HCV prevalence among those who share needles. 1 Hagan HJ, Pub Health Rep 2006;121:710

Conclusions Needle sharing remains common among IDU in community based treatment settings. Majority of IDUs obtained needles from drug stores and exchange programs HCV-aware IDU more frequently exhibited harm reduction behaviors: – Used needle exchange programs – Cleaned needles with bleach – Avoided drinking alcohol to intoxication BUT… were more likely to share needles/works

Implications Hepatitis C screening in treatment programs may identify clients in need of targeted harm reduction interventions. Interventions that decrease risky injection behaviors among IDU presenting for addiction treatment may reduce HCV transmission